{
    "clinical_study": {
        "@rank": "132702", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous (SC) injection of REGN1500 (Dose 1) or placebo SC"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "SC injection of REGN1500 (Dose 2) or placebo SC"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "SC injection of REGN1500 (Dose 3) or placebo SC"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous (IV) infusion of REGN1500 (Dose 4) or placebo IV"
            }, 
            {
                "arm_group_label": "Cohort 5", 
                "arm_group_type": "Experimental", 
                "description": "IV infusion of REGN1500 (Dose 5) or placebo IV"
            }, 
            {
                "arm_group_label": "Cohort 6", 
                "arm_group_type": "Experimental", 
                "description": "IV infusion of REGN1500 (Dose 6) or placebo IV"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase 1, first-in-human, randomized, ascending single-dose, placebo-controlled, double-blind\n      study of the safety, tolerability, and bioeffect of REGN1500"
        }, 
        "brief_title": "Study to Assess the Safety and Tolerability of Single Doses of REGN1500", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Body mass index 18.0 to 40.0 kg/m2, inclusive\n\n          2. Normal standard 12-lead ECG\n\n          3. Willing to refrain from the consumption of alcohol for 24 hours prior to each study\n             visit\n\n          4. Willing to consistently maintain his/her usual diet for the duration of the study\n\n          5. Willing to refrain from strenuous exercise for the duration of the trial\n\n          6. Willing and able to comply with clinic visits and study-related procedures\n\n          7. Provide signed informed consent\n\n          8. For sexually active men and women of childbearing potential, willingness to utilize\n             adequate contraception and not become pregnant (or have their partner[s] become\n             pregnant) during the full duration of the study.\n\n        Exclusion Criteria:\n\n          1. Any clinically significant abnormalities observed during the screening visit\n\n          2. History of drug or alcohol abuse within 1 year of screening\n\n          3. Receipt of another investigational drug or therapy within 30 days or at least 5\n             half-lives (whichever is longer), of the investigational drug prior to the screening\n             visit.\n\n          4. Significant concomitant illness or history of significant illness such as cardiac,\n             renal, neurological, endocrinological, metabolic or lymphatic disease, or any other\n             illness or condition that may adversely affect the subjects participation in this\n             study\n\n          5. Known history of human immunodeficiency virus (HIV) antibody; and/or positive\n             hepatitis B surface antigen (HBsAg), and/or positive hepatitis C antibody (HCV) at\n             the screening visit\n\n          6. Hospitalization for any reason within 60 days of screening\n\n          7. History or presence of malignancy within 5 years prior to the screening visit (other\n             than successfully treated non-metastatic cutaneous squamous cell or basal cell\n             carcinoma, and/or localized carcinoma in situ of the cervix\n\n          8. Any medical or psychiatric condition which, in the opinion of the investigator, would\n             place the subject at risk, interfere with participation in the study or interfere\n             with the interpretation of the study results\n\n          9. Any subject who is the investigator or any sub-investigator, research assistant,\n             pharmacist, study coordinator, or other staff directly involved in the conduct of the\n             protocol, or family member of staff involved in the conduct of the protocol\n\n         10. Pregnant or breast-feeding women\n\n        (The inclusion/ exclusion criteria provided above are not intended to contain all\n        considerations relevant to a patient's potential participation in this clinical trial)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749878", 
            "org_study_id": "R1500-HV-1214"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4", 
                    "Cohort 5", 
                    "Cohort 6"
                ], 
                "intervention_name": "REGN1500", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4", 
                    "Cohort 5", 
                    "Cohort 6"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miramar", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "overall_contact": {
            "email": "clinicaltrials@regeneron.com", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint in the study is the incidence and severity of treatment-emergent adverse events (TEAEs) through day 106/126 in participants treated with REGN1500.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 to Day 106/126"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749878"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Serum concentration of REGN1500 over time (summary statistics and PK parameters)", 
            "measure": "Serum concentration of REGN1500", 
            "safety_issue": "No", 
            "time_frame": "Day 1 to Day 106/126"
        }, 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}